The connection between PARP14 and SARS-CoV-2

Future Medicinal ChemistryVol. 15, No. 3 EditorialThe connection between PARP14 and SARS-CoV-2Amanda L Tauber, Stephanie S Schweiker & Stephan M LevonisAmanda L Tauber https://orcid.org/0000-0003-4668-9301Faculty of Health Sciences & Medicine, Bond University, Gold Coast, Queensland, 4229, AustraliaSearch for more papers by this author, Stephanie S Schweiker *Author for correspondence: E-mail Address: sschweik@bond.edu.auhttps://orcid.org/0000-0002-0978-2569Faculty of Health Sciences & Medicine, Bond University, Gold Coast, Queensland, 4229, AustraliaSearch for more papers by this author & Stephan M Levonis https://orcid.org/0000-0002-6538-7459Faculty of Health Sciences & Medicine, Bond University, Gold Coast, Queensland, 4229, AustraliaSearch for more papers by this authorPublished Online:3 Feb 2023https://doi.org/10.4155/fmc-2023-0013AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: ARTD8coronavirusCOVID-19immunityPARP14viralReferences1. Tauber AL, Schweiker SS, Levonis SM. The potential association between PARP14 and SARS-CoV-2 infection (COVID-19). Future Med. Chem. 13(6), 587–592 (2021).Link, CAS, Google Scholar2. Chen F, Shi Q, Pei F et al. A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection. Mol. Syst. Biol. 17(8), e10239 (2021).Crossref, Medline, CAS, Google Scholar3. Heer CD, Sanderson DJ, Voth LS et al. Coronavirus infection and PARP expression dysregulate the NAD metabolome: an actionable component of innate immunity. J Biol. Chem. 295(52), 17986–17996 (2020).Crossref, Medline, CAS, Google Scholar4. Desai N, Neyaz A, Szabolcs A et al. Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection. Nat.Comm. 11(1), 6319 (2020).Crossref, Medline, CAS, Google Scholar5. Rouchka EC, Chariker JH, Alejandro B et al. Induction of interferon response by high viral loads at early stage infection may protect against severe outcomes in COVID-19 patients. Sci. Rep. 11(1), 1–14 (2021).Crossref, Medline, Google Scholar6. Chen F, Zhang Y, Sucgang R et al. Meta-analysis of host transcriptional responses to SARS-CoV-2 infection reveals their manifestation in human tumors. Sci. Rep. 11(1), 2459 (2021).Crossref, Medline, CAS, Google Scholar7. Zheng M, Schultz MB, Sinclair DA. NAD+ in COVID-19 and viral infections. Trends Immunol. 43(4), 283–295 (2022).Crossref, Medline, CAS, Google Scholar8. Obando-Pereda G. Can molecular mimicry explain the cytokine storm of SARS-CoV-2?: An in silico approach. J. Med. Virol. 93(9), 5350–5357 (2021).Crossref, Medline, CAS, Google Scholar9. Alhammad YMO, Kashipathy MM, Roy A et al. The SARS-CoV-2 conserved macrodomain is a mono-ADP-ribosylhydrolase. J.Virol. 95(3), 1–20 (2021).Crossref, Google Scholar10. Fourkiotis NK, Charalampous P, Tsika AC et al. NMR study of human macroPARPs domains: 1H, 15N and 13C resonance assignment of hPARP14 macro domain 2 in the free and the ADPr bound state. Biomol. NMR Assign. 16(2), 399–406 (2022).Medline, CAS, Google Scholar11. O'Donoghue SI, Schafferhans A, Sikta N et al. SARS-CoV-2 structural coverage map reveals viral protein assembly, mimicry, and hijacking mechanisms. Mol. Syst. Biol. 17(9), e10079 (2021).Medline, Google Scholar12. Liu Y, Gan J, Wang R et al. DrugDevCovid19: an atlas of anti-COVID-19 compounds derived by computer-aided drug design. Molecules (Basel, Switzerland) 27(3), 683 (2022).Crossref, Medline, CAS, Google Scholar13. Vitali L, Merlini A, Galvagno F et al. Biological and exploitable crossroads for the immune response in cancer and COVID-19. Biomedicines 10(10), 2628 (2022).Crossref, Medline, CAS, Google Scholar14. Schweiker SS, Tauber AL, Sherry ME, Levonis SM. Structure, function and inhibition of poly(ADP-ribose)polymerase, member 14 (PARP14). Mini Rev. Med. Chem. 18(19), 1659–1669 (2018).Crossref, Medline, CAS, Google Scholar15. Jiang Y, Deng Y, Pang H et al. Treatment of SARS-CoV-2-induced pneumonia with NAD+ and NMN in two mouse models. Cell Dis. 8(1), 38 (2022).Crossref, Medline, CAS, Google Scholar16. Miller R, Wentzel AR, Richards GA. COVID-19: NAD+ deficiency may predispose the aged, obese and type2 diabetics to mortality through its effect on SIRT1 activity. Med. Hypoth. 144, 110044 (2020).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 15, No. 3 Follow us on social media for the latest updates Metrics Downloaded 28 times History Received 16 January 2023 Accepted 20 January 2023 Published online 3 February 2023 Published in print February 2023 Information© 2023 Newlands PressKeywordsARTD8coronavirusCOVID-19immunityPARP14viralFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download